Xvivo Q4 Initial take: Solid - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Xvivo Q4 Initial take: Solid - Redeye

{newsItem.title}

The most important aspects are organic growth and gross margins in our view. XVIVO delivers Q¤ organic growth of 27% well ahead of both out (+2%) and market expectations (+6). XVIVO also improves gross margins and delivers solid organic growth for all three business areas. We expect a positive initial market reaction of 3-5% and added support for the our structural XVIVO case.

Länk till analysen i sin helhet: https://www.redeye.se/research/872285/xvivo-q4-initial-take-solid?utm_source=finwire&utm_medium=RSS

Nyheter om Xvivo Perfusion

Läses av andra just nu

Om aktien Xvivo Perfusion

Senaste nytt